首页> 外文期刊>Mayo Clinic Proceedings >Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
【24h】

Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer

机译:肌肉侵袭尿路上皮癌的管理及免疫疗法在晚期尿路癌中的新兴作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The incidence of bladder cancer has increased in the past decade, and mortality from bladder cancer remains a substantial public health burden. After 3 decades of minimal progress in the treatment of advanced-stage disease, recent advances in the genomic characterization of urothelial cancer and breakthroughs in bladder cancer therapeutics have rejuvenated the field. This review highlights the landmark clinical trials of chemotherapy in both the neoadjuvant and advanced or metastatic urothelial carcinoma settings. We describe treatment paradigms for multimodal treatment of locally advanced bladder cancer, including discussion on bladder preservation strategies. Lastly, we discuss novel immunomodulatory, targeted, and combination therapies in development for the treatment of advanced urothelial carcinoma. (C) 2017 Mayo Foundation for Medical Education and Research
机译:过去十年膀胱癌的发病率增加,膀胱癌的死亡率仍然是一个大量的公共卫生负担。 在治疗晚期疾病的治疗过程中的最小进步后,膀胱癌治疗尿道癌的尿路上癌基因组特征的最新进展使得该领域恢复活力。 本综述突出了新辅助和晚期或转移性尿路上皮癌环境中化疗的标志性临床试验。 我们描述了局部晚期膀胱癌的多峰治疗的治疗范式,包括讨论膀胱保存策略。 最后,我们讨论了治疗晚期尿路上癌的开发的新型免疫调节性,靶向,和组合疗法。 (c)2017年医学教育和研究基金会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号